---
title: Diabetes Medications
type: content
phase: 1
status: complete
priority: high
tags: [diabetes, insulin, metformin, sulfonylureas, GLP-1-agonists, SGLT2-inhibitors, DPP-4-inhibitors, hyperglycemia]
created: 2025-11-08
last_modified: 2025-11-08
---

# Diabetes Medications

## Introduction

Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia due to defects in insulin secretion, insulin action, or both. Understanding the diverse pharmacologic options for managing type 1 and type 2 diabetes is essential for optimizing glycemic control and preventing complications while minimizing adverse effects.

## Classification

### Type 1 Diabetes (Absolute Insulin Deficiency)
- **Treatment**: **Insulin required** (multiple daily injections or pump)

### Type 2 Diabetes (Insulin Resistance + Relative Insulin Deficiency)
- **Treatment**: Lifestyle + oral agents ± insulin

### Drug Classes

**Insulin**:
- Rapid-acting, short-acting, intermediate-acting, long-acting

**Oral/Injectable Non-Insulin Agents**:

1. **Biguanides**: Metformin
2. **Sulfonylureas**: Glyburide, glipizide, glimepiride
3. **Meglitinides**: Repaglinide, nateglinide
4. **Thiazolidinediones (TZDs)**: Pioglitazone, rosiglitazone
5. **DPP-4 Inhibitors** ("-gliptins"): Sitagliptin, saxagliptin, linagliptin
6. **GLP-1 Receptor Agonists** ("-glutides"): Exenatide, liraglutide, semaglutide, dulaglutide
7. **SGLT2 Inhibitors** ("-gliflozins"): Canagliflozin, dapagliflozin, empagliflozin
8. **α-Glucosidase Inhibitors**: Acarbose, miglitol
9. **Amylin Analog**: Pramlintide

---

## Insulin

### Physiology of Insulin

**Normal Secretion**:
- **Basal insulin** (50%): Constant low-level secretion (suppresses hepatic glucose production)
- **Prandial insulin** (50%): Meal-stimulated bolus (handles postprandial glucose)

**Actions**:
- **Anabolic hormone**:
  - ↑Glucose uptake (muscle, adipose) via GLUT4
  - ↓Hepatic glucose production (gluconeogenesis, glycogenolysis)
  - ↑Glycogen synthesis
  - ↑Protein synthesis, ↓proteolysis
  - ↑Lipogenesis, ↓lipolysis
  - ↓Ketogenesis
- **↓Serum K+** (shifts K+ intracellularly)

### Insulin Preparations

**Classification by Duration**:

#### Rapid-Acting Analogs

**Agents**:
- **Lispro** (Humalog)
- **Aspart** (Novolog)
- **Glulisine** (Apidra)

**Structure**: Modified human insulin (altered amino acid sequence)

**Pharmacokinetics**:
- **Onset**: 5-15 minutes
- **Peak**: 1-2 hours
- **Duration**: 3-5 hours

**Administration**:
- SC injection immediately before meals (0-15 minutes)
- IV (critical care)

**Clinical Uses**:
1. **Prandial (bolus) insulin** for meals
2. **Correction doses** for hyperglycemia
3. **Insulin pumps** (continuous SC infusion)
4. **Diabetic ketoacidosis** (DKA) - IV

**Advantages**:
- **Mimics physiologic prandial insulin**
- **Flexibility**: Inject just before eating
- **Lower postprandial hyperglycemia**
- **Lower risk of delayed hypoglycemia** (vs. regular insulin)

#### Short-Acting (Regular Insulin)

**Agents**:
- **Regular insulin** (Humulin R, Novolin R)

**Structure**: Unmodified human insulin

**Pharmacokinetics**:
- **Onset**: 30 minutes
- **Peak**: 2-4 hours
- **Duration**: 6-8 hours

**Administration**:
- SC injection 30 minutes before meals
- **IV** (preferred for DKA, critical care)

**Clinical Uses**:
1. Prandial insulin (less commonly used now - replaced by rapid-acting)
2. **IV insulin infusion** (DKA, hyperglycemic emergencies, perioperative)
3. **Sliding scale** (institutional settings)

**Note**: **Only insulin that can be given IV** (besides rapid-acting analogs)

#### Intermediate-Acting

**Agent**:
- **NPH** (Neutral Protamine Hagedorn) (Humulin N, Novolin N)

**Structure**: Human insulin + protamine (protein that delays absorption)

**Pharmacokinetics**:
- **Onset**: 1-2 hours
- **Peak**: 4-12 hours
- **Duration**: 12-24 hours

**Administration**:
- SC injection once or twice daily
- **Cloudy appearance** (must resuspend before injection)

**Clinical Uses**:
1. **Basal insulin** (especially BID dosing)
2. **Mixed with rapid/short-acting** (70/30, 75/25 formulations)
3. Type 2 diabetes (basal insulin initiation)

**Disadvantages**:
- **Pronounced peak** → ↑hypoglycemia risk (especially nocturnal)
- Requires consistent meal timing
- BID dosing usually needed

#### Long-Acting Analogs

**Agents**:
- **Glargine** (Lantus, Basaglar, Toujeo)
- **Detemir** (Levemir)

**Structure**: Modified human insulin (prolonged absorption)

**Pharmacokinetics**:
- **Onset**: 1-2 hours
- **Peak**: Minimal to no peak ("peakless")
- **Duration**:
  - Glargine: ~24 hours
  - Detemir: 16-24 hours (dose-dependent)

**Administration**:
- SC injection once daily (glargine) or BID (detemir)
- **Clear appearance** (unlike NPH)
- **Cannot mix** with other insulins

**Clinical Uses**:
1. **Basal insulin** (preferred over NPH)
2. Type 1 diabetes (basal-bolus regimen)
3. Type 2 diabetes (basal insulin)

**Advantages**:
- **Peakless profile** → ↓hypoglycemia risk (especially nocturnal)
- **Once-daily dosing** (usually)
- **More predictable** than NPH
- Better fasting glucose control

#### Ultra-Long-Acting Analogs

**Agents**:
- **Degludec** (Tresiba)
- **Glargine U-300** (Toujeo - concentrated glargine)

**Pharmacokinetics**:
- **Onset**: 1-2 hours
- **Peak**: Minimal
- **Duration**: **>42 hours** (degludec), ~36 hours (glargine U-300)

**Advantages**:
- **Very stable, flat profile**
- **Lower hypoglycemia risk** than glargine U-100
- **Flexible injection timing** (degludec - can vary by several hours)
- May allow once-daily dosing in more patients

### Premixed Insulins

**Combinations**: Rapid/short-acting + intermediate-acting
- **70/30**: 70% NPH + 30% regular
- **75/25**: 75% insulin lispro protamine + 25% lispro
- **70/30**: 70% insulin aspart protamine + 30% aspart
- **50/50**: 50% NPH + 50% regular

**Advantages**:
- **Convenience** (single injection provides basal + prandial)
- ↓Number of injections

**Disadvantages**:
- **Less flexible** (fixed ratio)
- Requires consistent meal timing, carbohydrate intake
- ↑Hypoglycemia risk

**Clinical Uses**: Type 2 diabetes (simplified regimen)

### Insulin Regimens

#### Type 1 Diabetes (Intensive Insulin Therapy)

**Basal-Bolus Regimen** (Preferred):
- **Basal**: Long-acting insulin once daily (glargine, detemir, degludec)
- **Bolus**: Rapid-acting before each meal (lispro, aspart, glulisine)
- **Total daily dose**: ~0.5-1 unit/kg
  - 50% basal, 50% bolus (divided among meals)
- **Carbohydrate counting**: Adjust bolus based on meal

**Insulin Pump** (Continuous SC Insulin Infusion - CSII):
- Rapid-acting insulin only
- **Basal rate**: Continuous programmable infusion
- **Bolus**: Patient-activated for meals, corrections
- Most physiologic delivery

#### Type 2 Diabetes (Stepwise Approach)

**Step 1**: Lifestyle + metformin

**Step 2**: Add second agent (GLP-1 agonist, SGLT2 inhibitor, DPP-4 inhibitor, sulfonylurea, TZD)

**Step 3**: Add basal insulin or triple therapy
- **Basal insulin initiation**:
  - Start: 10 units daily or 0.1-0.2 units/kg
  - Titrate: ↑2-4 units every 3 days until fasting glucose at goal
  - Continue oral agents (metformin)

**Step 4**: Intensify insulin
- Add prandial insulin (basal-bolus) or switch to premixed

### Insulin Adverse Effects

**Hypoglycemia** (Most Important):
- **Definition**: Blood glucose <70 mg/dL
- **Symptoms**:
  - **Autonomic**: Tremor, palpitations, sweating, anxiety, hunger
  - **Neuroglycopenic**: Confusion, dizziness, weakness, vision changes, seizures, coma
- **Risk Factors**: Missed meals, excessive dose, exercise, alcohol, renal failure
- **Treatment**:
  - **Conscious**: Oral glucose 15-20 g (glucose tablets, juice)
  - **Unconscious**: Glucagon 1 mg IM/SC or IV dextrose
- **Prevention**: Patient education, glucose monitoring

**Weight Gain**:
- Anabolic effect
- ~2-4 kg average

**Lipohypertrophy**:
- Subcutaneous fat accumulation at injection sites
- Impairs absorption
- Prevention: Rotate injection sites

**Hypokalemia**:
- Insulin shifts K+ intracellularly
- Risk in DKA treatment (monitor K+)

**Edema**:
- Sodium retention (transient)

**Insulin Allergy** (Rare):
- Local reaction or systemic
- More common with animal insulins (less with human/analogs)

### Insulin Drug Interactions

**↑Hypoglycemia Risk**:
- Alcohol (inhibits gluconeogenesis)
- β-Blockers (mask hypoglycemia symptoms)
- Salicylates, sulfonamides
- ACE inhibitors

**↓Insulin Effect (↑glucose)**:
- Corticosteroids
- Thiazide diuretics
- Sympathomimetics
- Atypical antipsychotics

### Clinical Pearls - Insulin

- **Type 1 requires insulin** (basal-bolus regimen)
- **Rapid-acting analogs best for prandial** (inject at mealtime)
- **Long-acting analogs better than NPH** (less hypoglycemia)
- **Insulin dose**: ~0.5-1 unit/kg total daily (50% basal, 50% bolus)
- **Hypoglycemia most important adverse effect** - educate patients
- **Rotate injection sites** (prevent lipohypertrophy)
- **Store unopened insulin in refrigerator**, **opened at room temp** (<30 days)

---

## Metformin (Biguanide)

### Mechanism of Action

**Primary**: **↓Hepatic glucose production** (gluconeogenesis)
- Activates AMP-activated protein kinase (AMPK)
- Inhibits mitochondrial complex I

**Secondary**:
- ↑Peripheral glucose uptake (muscle)
- ↓Intestinal glucose absorption
- ↑GLP-1 secretion
- ↓Weight (modest)

**Key Feature**: **Does NOT cause hypoglycemia** (does not stimulate insulin secretion)

### Pharmacokinetics

- Oral (immediate-release, extended-release)
- **Not metabolized** (excreted unchanged in urine)
- Half-life: 4-9 hours

### Clinical Uses

1. **Type 2 diabetes** - **FIRST-LINE** (with lifestyle)
2. **Prediabetes** (prevention)
3. **Polycystic ovarian syndrome (PCOS)** (off-label)
4. **Metabolic syndrome**

### Advantages

- **First-line for type 2 diabetes** (ADA/EASD guidelines)
- **No hypoglycemia** (monotherapy)
- **Weight neutral or modest weight loss** (1-2 kg)
- **Cardiovascular neutral** (does not increase CV risk)
- **Inexpensive** (generic)
- Possible ↓cancer risk

### Adverse Effects

**GI Effects** (Most Common, 20-30%):
- Diarrhea, nausea, abdominal discomfort
- **Dose-related**, usually transient (first weeks)
- **Mitigation**: Start low dose, titrate slowly, take with meals, use ER formulation

**Vitamin B12 Deficiency** (Long-term, 10-30%):
- Mechanism: ↓B12 absorption
- **Monitor B12** in long-term users (annually)
- Supplement if deficient

**Lactic Acidosis** (Rare, <0.03 per 1000 patient-years):
- **Life-threatening** but very rare
- Risk factors: Renal failure, liver disease, hypoxia, sepsis, alcohol
- **Contraindicated** in severe renal impairment (see below)
- **Hold metformin** perioperatively if contrast dye used

**Other**:
- Metallic taste

### Contraindications

**Updated FDA 2016** (less restrictive than before):
- **eGFR <30 mL/min/1.73m²**: Contraindicated
- **eGFR 30-45**: Use caution, consider dose reduction
- **eGFR ≥45**: Safe to use
- **Acute kidney injury** or risk factors
- **Severe hepatic impairment**
- **Acute heart failure**, severe CHF
- **Hypoxic states**: Severe respiratory disease, sepsis, shock
- **Acute alcohol intoxication**, chronic alcoholism
- **Contrast dye procedures**: Hold 48 hours after (check renal function)

### Dosing

- Start: 500 mg once or twice daily (with meals)
- Titrate: ↑500 mg weekly
- Max: 2000-2550 mg/day (divided BID or TID)
- **ER formulation**: Once daily, better GI tolerability

### Clinical Pearls

- **First-line for type 2 diabetes** (unless contraindicated)
- **No hypoglycemia** (safe monotherapy)
- **GI side effects common** - start low, titrate slow, use ER
- **Check B12 annually** in long-term users
- **Check renal function** (contraindicated if eGFR <30)
- **Hold for contrast dye procedures** (lactic acidosis risk)

---

## Sulfonylureas

### Mechanism of Action

**Target**: ATP-sensitive K+ channels on pancreatic β-cells

**Mechanism**:
1. Bind to SUR1 receptor on K+ channel
2. **Close K+ channel** → depolarization
3. Open voltage-gated Ca2+ channels
4. **↑Insulin secretion** (Ca2+-dependent)

**Effect**: **↑Insulin secretion** (glucose-independent)

### Individual Agents

**Second-Generation** (Preferred):

**Glyburide (Glibenclamide)** (Micronase, DiaBeta):
- Most potent
- **Highest hypoglycemia risk**
- Duration: 12-24 hours
- Dosing: 1.25-20 mg/day (divided or once daily)

**Glipizide** (Glucotrol):
- Intermediate potency
- Duration: 12-24 hours
- **May have less hypoglycemia** than glyburide
- Dosing: 2.5-40 mg/day (divided or XL once daily)

**Glimepiride** (Amaryl):
- Long-acting
- **Once-daily dosing**
- **Lower hypoglycemia risk** than glyburide
- Dosing: 1-8 mg once daily

**First-Generation** (Rarely Used):
- Chlorpropamide, tolbutamide, tolazamide

### Pharmacokinetics

- Oral
- Hepatic metabolism
- Variable duration (see above)

### Clinical Uses

1. **Type 2 diabetes** (add-on to metformin or alternative if metformin not tolerated)
2. **NOT for type 1 diabetes** (requires β-cell function)

### Advantages

- **Effective glucose lowering** (↓HbA1c ~1-2%)
- **Inexpensive** (generic)
- **Once-daily dosing** (glimepiride, XL formulations)
- Rapid onset of action

### Adverse Effects

**Hypoglycemia** (Major Concern):
- **Most significant adverse effect**
- Risk: Elderly, renal impairment, irregular meals, alcohol
- **Glyburide highest risk** (avoid in elderly)
- Can be **severe and prolonged** (hours)

**Weight Gain**:
- Average 2-5 kg
- Mechanism: ↑insulin secretion (anabolic)

**Other**:
- Nausea
- Rash, photosensitivity (rare)
- Disulfiram-like reaction with alcohol (chlorpropamide)

**Cardiovascular Safety**:
- Controversial - may ↑CV risk vs. metformin
- UKPDS: No ↑CV risk
- Ongoing debate

### Contraindications

- Type 1 diabetes
- Diabetic ketoacidosis
- Severe hepatic or renal impairment
- Sulfa allergy (relative)
- Pregnancy, breastfeeding

### Drug Interactions

**↑Hypoglycemia Risk** (↑sulfonylurea levels or effect):
- Sulfonamides, trimethoprim
- Fluconazole, miconazole
- Warfarin
- Salicylates
- Gemfibrozil
- Alcohol

**↓Effect**:
- Rifampin (CYP inducer)
- Thiazides, corticosteroids (↑glucose)

### Clinical Pearls

- **Effective and inexpensive** - commonly used
- **Hypoglycemia major concern** (especially glyburide in elderly)
- **Glimepiride preferred** (once-daily, lower hypoglycemia risk)
- **Avoid glyburide in elderly, renal impairment**
- **Weight gain** (less favorable than metformin, GLP-1, SGLT2)
- **Second-line to metformin** (or combination)

---

## Meglitinides (Glinides)

### Mechanism

Similar to sulfonylureas (bind different site on K+ channel)
- **↑Insulin secretion** (rapid, short-duration)

### Agents

**Repaglinide** (Prandin):
- Dosing: 0.5-4 mg before each meal

**Nateglinide** (Starlix):
- Dosing: 60-120 mg before each meal

### Pharmacokinetics

- Oral
- **Rapid onset** (30 minutes)
- **Short duration** (3-4 hours)

### Clinical Uses

- Type 2 diabetes (control postprandial glucose)
- **Take immediately before meals** (0-30 minutes)
- **Skip if skip meal**

### Advantages

- **Control postprandial glucose spikes**
- Flexible (skip dose if skip meal)
- Lower hypoglycemia risk than sulfonylureas (shorter duration)

### Adverse Effects

- Hypoglycemia (less than sulfonylureas)
- Weight gain (modest)

### Clinical Pearls

- **Less commonly used** (TID dosing, cost)
- **Good for postprandial hyperglycemia** if irregular meal schedule
- **Lower hypoglycemia than sulfonylureas** (shorter duration)

---

## Thiazolidinediones (TZDs) - Glitazones

### Mechanism

**Target**: **PPARγ (peroxisome proliferator-activated receptor gamma)**
- Nuclear transcription factor in adipocytes, muscle, liver

**Effects**:
- **↑Insulin sensitivity** (muscle, liver, adipose)
- ↓Hepatic glucose production
- ↑Glucose uptake
- Adipocyte differentiation (small subcutaneous adipocytes)
- Anti-inflammatory effects

**Key**: **Improve insulin sensitivity** (do not stimulate insulin secretion → no hypoglycemia)

### Agents

**Pioglitazone** (Actos):
- Preferred TZD (still available)
- Dosing: 15-45 mg once daily

**Rosiglitazone** (Avandia):
- Restricted use (cardiovascular concerns)
- Dosing: 4-8 mg once daily (divided or once daily)

### Pharmacokinetics

- Oral, once daily
- Hepatic metabolism
- **Slow onset** (weeks to months for full effect)

### Clinical Uses

1. Type 2 diabetes (add-on to metformin)
2. **NOT first-line** (adverse effects)

### Advantages

- **↑Insulin sensitivity** (addresses underlying pathophysiology)
- **No hypoglycemia** (monotherapy)
- ↓Triglycerides, ↑HDL (pioglitazone)
- May preserve β-cell function
- Possible cardiovascular benefit (pioglitazone in secondary prevention)

### Adverse Effects

**Fluid Retention/Edema** (5-15%):
- Mechanism: Renal sodium retention
- **Contraindicated in heart failure** (can precipitate or worsen CHF)
- **Black Box Warning**: CHF

**Weight Gain**:
- Significant (2-5 kg)
- Fluid retention + adipogenesis

**Bone Fractures** (Women):
- ↑Fracture risk (especially postmenopausal women)
- Distal extremities (arms, legs)
- Monitor bone health

**Hepatotoxicity** (Rare):
- **Troglitazone withdrawn** (1990s) due to fatal hepatotoxicity
- Pioglitazone, rosiglitazone: Rare, but monitor LFTs

**Bladder Cancer** (Pioglitazone):
- Possible ↑risk (controversial)
- **Avoid in active bladder cancer** or history

**Macular Edema**:
- Rare, can impair vision

**Cardiovascular** (Rosiglitazone):
- **Increased MI risk** (controversial, led to restricted use)
- Pioglitazone: May reduce CV events in high-risk patients (PROactive trial)

### Contraindications

- **Heart failure** (NYHA Class III-IV) - **Black Box Warning**
- Active liver disease
- Bladder cancer (pioglitazone)
- Pregnancy

### Clinical Pearls

- **Not first-line** (adverse effects: weight gain, edema, fractures, CHF)
- **Contraindicated in heart failure**
- **Slow onset** (weeks to months)
- **Monitor for edema**, weight gain
- **Pioglitazone preferred** (cardiovascular, lipid benefits)
- **Use declining** due to newer agents (GLP-1, SGLT2)

---

## DPP-4 Inhibitors (-gliptins)

### Mechanism

**Target**: **Dipeptidyl peptidase-4 (DPP-4)** enzyme

**Mechanism**:
- **Inhibit DPP-4** → ↑GLP-1, ↑GIP (incretin hormones)
- GLP-1/GIP effects:
  - ↑Insulin secretion (glucose-dependent)
  - ↓Glucagon secretion
  - ↓Appetite (modest)

**Key**: **Glucose-dependent** → low hypoglycemia risk

### Agents

**Sitagliptin** (Januvia):
- Dosing: 100 mg once daily (adjust for renal function)

**Saxagliptin** (Onglyza):
- Dosing: 2.5-5 mg once daily

**Linagliptin** (Tradjenta):
- Dosing: 5 mg once daily
- **No renal adjustment** (hepatic elimination)

**Alogliptin** (Nesina):
- Dosing: 25 mg once daily (adjust for renal function)

### Pharmacokinetics

- Oral, once daily
- Renal excretion (except linagliptin)

### Clinical Uses

1. Type 2 diabetes (add-on to metformin or alternative)
2. Combination pills: Metformin/sitagliptin (Janumet), others

### Advantages

- **Well-tolerated** (minimal side effects)
- **Low hypoglycemia risk** (glucose-dependent mechanism)
- **Weight neutral**
- **Once-daily dosing**
- **Oral** (vs. GLP-1 agonists - injectable)

### Adverse Effects

**Generally Well-Tolerated**:

**Nasopharyngitis, Upper Respiratory Infections** (common):
- Unclear if drug-related

**Pancreatitis** (Rare):
- Possible ↑risk (controversial)
- **Discontinue if pancreatitis** suspected

**Heart Failure** (Saxagliptin):
- ↑Heart failure hospitalizations (SAVOR-TIMI 53 trial)
- **Caution in heart failure risk**

**Hypersensitivity Reactions**:
- Angioedema, urticaria, anaphylaxis (rare)

**Joint Pain**:
- Severe, disabling (rare)

### Clinical Pearls

- **Well-tolerated, weight neutral** - good option
- **Low hypoglycemia risk** (safe)
- **Oral** (advantage over GLP-1 agonists)
- **Modest efficacy** (↓HbA1c 0.5-0.8%) - less than GLP-1, SGLT2
- **Linagliptin for renal impairment** (no adjustment needed)
- **Saxagliptin: Caution in heart failure** (↑hospitalization risk)

---

## GLP-1 Receptor Agonists (-glutides)

### Mechanism

**GLP-1 (Glucagon-Like Peptide-1)**: Incretin hormone from intestinal L-cells

**Actions**:
1. **↑Insulin secretion** (glucose-dependent)
2. **↓Glucagon secretion**
3. **↓Gastric emptying** (satiety)
4. **↑Satiety** (central appetite suppression)
5. Possible β-cell preservation

**Result**: ↓Glucose, **weight loss**

### Agents

**Short-Acting**:
- **Exenatide** (Byetta): BID (discontinued often)
- **Lixisenatide** (Adlyxin): Once daily

**Long-Acting**:
- **Exenatide ER** (Bydureon): Weekly
- **Liraglutide** (Victoza): Once daily
- **Dulaglutide** (Trulicity): Weekly
- **Semaglutide** (Ozempic): Weekly
- **Semaglutide oral** (Rybelsus): Once daily (first oral GLP-1)

### Pharmacokinetics

- **Injectable** (SC) - except oral semaglutide
- Variable duration (see above)

### Clinical Uses

1. **Type 2 diabetes** (add-on to metformin or other agents)
2. **Weight loss** (liraglutide 3 mg - Saxenda, semaglutide 2.4 mg - Wegovy)
3. **Cardiovascular risk reduction** (liraglutide, semaglutide, dulaglutide - FDA-approved)

### Advantages

**Excellent Efficacy**:
- **↓HbA1c 1-1.5%** (superior to DPP-4 inhibitors)

**Weight Loss**:
- **Significant weight loss** (3-5 kg, some patients >10 kg)
- **Unique among diabetes drugs** (most cause weight gain)

**Cardiovascular Benefits**:
- **Proven CV risk reduction** (liraglutide, semaglutide, dulaglutide)
- LEADER trial (liraglutide): ↓CV death, MI, stroke
- SUSTAIN-6 (semaglutide): ↓CV death, MI, stroke
- REWIND (dulaglutide): ↓CV events

**Renal Benefits**:
- ↓Albuminuria progression

**Low Hypoglycemia Risk**:
- Glucose-dependent mechanism

### Adverse Effects

**GI Effects** (Very Common, 40-50%):
- **Nausea, vomiting, diarrhea**
- **Dose-related**, usually improve over weeks
- **Major limitation** (discontinuation rate 5-10%)
- **Mitigation**: Slow titration, take with food

**Pancreatitis** (Rare):
- Possible ↑risk (controversial)
- **Discontinue if pancreatitis**

**Gallbladder Disease**:
- ↑Cholelithiasis, cholecystitis (weight loss-related)

**Thyroid C-Cell Tumors** (Animal Studies):
- **Black Box Warning**: Medullary thyroid carcinoma (MTC) in rodents
- **Contraindicated**: Personal/family history of MTC, MEN 2
- Human relevance unclear (no evidence of ↑risk in humans)

**Injection Site Reactions**:
- Redness, itching

**Hypoglycemia** (When Combined with Sulfonylureas/Insulin):
- Reduce sulfonylurea/insulin dose when adding GLP-1

**Diabetic Retinopathy Worsening** (Semaglutide):
- Rapid glucose lowering may worsen retinopathy temporarily

### Contraindications

- **Personal or family history of medullary thyroid carcinoma**
- **Multiple endocrine neoplasia syndrome type 2 (MEN 2)**
- Pregnancy
- History of pancreatitis (relative)

### Dosing Examples

**Liraglutide (Victoza)**:
- Start: 0.6 mg daily × 1 week
- ↑To 1.2 mg daily
- Max: 1.8 mg daily

**Semaglutide (Ozempic)**:
- Start: 0.25 mg weekly × 4 weeks
- ↑To 0.5 mg weekly
- Max: 2 mg weekly (if needed)

**Dulaglutide (Trulicity)**:
- Start: 0.75 mg weekly
- ↑To 1.5 mg weekly

### Clinical Pearls

- **Highly effective** (↓HbA1c, weight loss, CV benefit)
- **Injectable** (barrier for some patients) - weekly preferred
- **GI side effects common** (nausea) - slow titration essential
- **Weight loss** - excellent for overweight/obese patients
- **CV benefit proven** (liraglutide, semaglutide, dulaglutide) - **preferred in ASCVD**
- **Contraindicated in MTC/MEN 2** (Black Box)
- **First oral GLP-1**: Semaglutide (Rybelsus) - take on empty stomach

---

## SGLT2 Inhibitors (-gliflozins)

### Mechanism

**Target**: **Sodium-glucose cotransporter 2 (SGLT2)** in proximal renal tubule

**Mechanism**:
- **Inhibit glucose reabsorption** in kidney
- **↑Urinary glucose excretion** (~70-90 g/day)
- **Insulin-independent** mechanism

**Secondary Effects**:
- Weight loss (calorie loss)
- BP reduction (osmotic diuresis)
- ↓Uric acid

### Agents

**Canagliflozin** (Invokana):
- Dosing: 100-300 mg once daily

**Dapagliflozin** (Farxiga):
- Dosing: 5-10 mg once daily

**Empagliflozin** (Jardiance):
- Dosing: 10-25 mg once daily

**Ertugliflozin** (Steglatro):
- Dosing: 5-15 mg once daily

### Pharmacokinetics

- Oral, once daily
- Hepatic metabolism
- Long half-life

### Clinical Uses

1. **Type 2 diabetes** (add-on to metformin)
2. **Heart failure** (HFrEF and HFpEF) - FDA-approved indications expanding
3. **Chronic kidney disease** (slow progression)

### Advantages

**Excellent Efficacy**:
- **↓HbA1c 0.5-1%**

**Weight Loss**:
- **Modest weight loss** (2-3 kg)
- Calorie loss via glycosuria

**Cardiovascular Benefits** (Proven):
- **↓CV death** (empagliflozin, canagliflozin)
- **EMPA-REG OUTCOME** (empagliflozin): ↓CV death 38%, ↓HF hospitalization 35%
- **CANVAS** (canagliflozin): ↓CV events
- **DECLARE-TIMI 58** (dapagliflozin): ↓HF hospitalization

**Heart Failure Benefits**:
- **↓HF hospitalization** (all SGLT2 inhibitors)
- **Benefit in HFrEF and HFpEF** (even without diabetes)
- **DAPA-HF**, **EMPEROR-Reduced**, **EMPEROR-Preserved**

**Renal Protection**:
- **Slow CKD progression**, ↓albuminuria
- **CREDENCE** (canagliflozin), **DAPA-CKD** (dapagliflozin): ↓Kidney disease progression

**Blood Pressure Reduction**:
- Modest ↓BP (3-5 mmHg systolic)

**Low Hypoglycemia Risk**:
- Insulin-independent mechanism

### Adverse Effects

**Genitourinary Infections** (Common, 10-20%):
- **Genital mycotic infections** (vulvovaginal candidiasis, balanitis):
  - Due to glycosuria (glucose in urine)
  - **Most common adverse effect**
  - More common in women
  - Treat with topical antifungals
- **Urinary tract infections** (less common than genital)

**Osmotic Diuresis Effects**:
- **Volume depletion**: Dizziness, orthostatic hypotension
- **Dehydration** (especially elderly)
- ↑Creatinine (transient, due to volume contraction)

**Diabetic Ketoacidosis (DKA)** (Rare):
- **Euglycemic DKA** (normal glucose but ketoacidosis)
- Risk: Type 1 diabetes, insulin deficiency, illness, surgery
- **Mechanism**: Glucosuria → ↓insulin, ↑glucagon → ketogenesis
- **Discontinue before surgery**

**Acute Kidney Injury**:
- Volume depletion in susceptible patients
- Monitor renal function

**Bone Fractures** (Canagliflozin):
- Possible ↑fracture risk (CANVAS trial)

**Amputations** (Canagliflozin):
- **↑Lower limb amputations** (CANVAS trial - mostly toes)
- Controversial - other SGLT2 inhibitors not affected
- **Foot care education** important

**Fournier's Gangrene** (Rare):
- Necrotizing fasciitis of perineum
- **Medical emergency**

**Hypotension**:
- Osmotic diuresis

### Contraindications

- **Severe renal impairment** (eGFR <30) - ineffective (except dapagliflozin approved down to eGFR 25 for CKD)
- Type 1 diabetes (DKA risk) - some approved with caution
- Dialysis

### Clinical Pearls

- **Highly effective with CV and renal benefits** - **preferred in ASCVD, HF, CKD**
- **Genital infections common** - counsel patients (especially women)
- **Weight loss, BP reduction** - favorable
- **Euglycemic DKA risk** - discontinue before surgery, illness
- **Empagliflozin, dapagliflozin preferred** (proven CV benefit, no amputation signal)
- **Heart failure indication**: Even without diabetes
- **CKD protection**: FDA-approved for slowing progression

---

## α-Glucosidase Inhibitors

### Mechanism

**Target**: α-Glucosidase enzymes in small intestine brush border

**Mechanism**:
- **Inhibit carbohydrate digestion**
- Delay breakdown of complex carbs → glucose, fructose, galactose
- **↓Postprandial glucose spike**

### Agents

**Acarbose** (Precose):
- Dosing: 25-100 mg TID with meals

**Miglitol** (Glyset):
- Dosing: 25-100 mg TID with meals

### Clinical Uses

- Type 2 diabetes (postprandial hyperglycemia)
- **Take with first bite of meal**

### Advantages

- **No hypoglycemia** (does not affect insulin)
- **Weight neutral**
- ↓Postprandial glucose

### Adverse Effects

**GI Effects** (Very Common, 70%):
- **Flatulence, diarrhea, abdominal pain, bloating**
- Mechanism: Undigested carbohydrates fermented by colonic bacteria
- **Major limitation** (high discontinuation)
- **Improve with time** (weeks)

**Hepatotoxicity** (Rare):
- Monitor LFTs

### Clinical Pearls

- **Modest efficacy** (↓HbA1c 0.5-0.8%)
- **GI side effects limit use** (flatulence, diarrhea)
- **Take with first bite of meal**
- **Rarely used** in US (better-tolerated options available)
- **If hypoglycemia on combination**: Treat with **glucose** (not sucrose - will not work)

---

## Treatment Approach to Type 2 Diabetes

### Initial Therapy

**Step 1**: **Lifestyle + Metformin**
- Metformin first-line (unless contraindicated)

### Intensification (If HbA1c Not at Goal)

**Step 2**: Add second agent based on patient factors:

**Established ASCVD or High CV Risk**:
- **GLP-1 agonist** (with proven CV benefit) OR **SGLT2 inhibitor** (with proven CV benefit)

**Heart Failure**:
- **SGLT2 inhibitor** (proven HF benefit)

**Chronic Kidney Disease**:
- **SGLT2 inhibitor** OR **GLP-1 agonist** (renal protection)

**Need to Minimize Hypoglycemia**:
- **DPP-4 inhibitor**, **GLP-1 agonist**, **SGLT2 inhibitor**, **TZD** (avoid sulfonylureas)

**Weight Loss Priority**:
- **GLP-1 agonist** (best weight loss) OR **SGLT2 inhibitor**

**Cost Priority**:
- **Sulfonylurea** OR **TZD** (generic, inexpensive)

### Step 3: Triple Therapy or Insulin

**If HbA1c still not at goal**:
- Add third oral agent OR **add basal insulin**

**Basal Insulin**:
- Start 10 units daily or 0.1-0.2 units/kg
- Continue metformin (±other oral agents)
- Titrate to fasting glucose goal

### Step 4: Intensify Insulin

- Add prandial insulin (basal-bolus)
- OR switch to premixed insulin

### HbA1c Goals

**Individualized**:
- **General goal**: <7% (ADA), <6.5% (AACE) for most
- **Less stringent** (<8%): Elderly, limited life expectancy, hypoglycemia risk, advanced complications
- **More stringent** (<6.5%): Young, short duration, no CV disease (if achievable without hypoglycemia)

---

## Clinical Pearls - General

1. **Metformin first-line** (unless contraindicated) - effective, safe, inexpensive
2. **GLP-1 and SGLT2 preferred in ASCVD, HF, CKD** - proven CV/renal benefits
3. **Insulin required for type 1 diabetes** - basal-bolus regimen
4. **Hypoglycemia risk highest**: Insulin, sulfonylureas (esp. glyburide)
5. **Weight loss**: GLP-1 agonists (best), SGLT2 inhibitors, metformin
6. **Weight gain**: Insulin, sulfonylureas, TZDs
7. **Avoid sulfonylureas in elderly** (hypoglycemia risk)
8. **TZDs contraindicated in heart failure**
9. **SGLT2 inhibitors cause genital infections** - counsel patients
10. **Check B12 on metformin long-term**
11. **GLP-1 nausea common** - slow titration
12. **DPP-4 inhibitors well-tolerated** but modest efficacy

---

## Key Takeaways

1. **Insulin**: Required for type 1, multiple formulations (rapid, short, intermediate, long, ultra-long), hypoglycemia main risk
2. **Metformin**: First-line for type 2, ↓hepatic glucose, no hypoglycemia, GI side effects, check B12
3. **Sulfonylureas**: ↑Insulin secretion, hypoglycemia and weight gain, avoid glyburide in elderly
4. **GLP-1 agonists**: Injectable, ↑insulin (glucose-dependent), weight loss, CV benefit, nausea common
5. **SGLT2 inhibitors**: ↑Urinary glucose, weight loss, CV/HF/renal benefits, genital infections common
6. **DPP-4 inhibitors**: Oral, well-tolerated, weight neutral, modest efficacy
7. **TZDs**: ↑Insulin sensitivity, weight gain, edema, contraindicated in CHF
8. **Treatment approach**: Metformin first, add GLP-1/SGLT2 if ASCVD/HF/CKD, individualize based on patient factors
9. **Hypoglycemia treatment**: Glucose 15-20 g PO (conscious) or glucagon 1 mg IM (unconscious)
10. **HbA1c goal**: Individualized, generally <7% for most patients

---

## References

1. American Diabetes Association Standards of Care in Diabetes - 2025
2. Katzung's Basic & Clinical Pharmacology, 15th Edition
3. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
4. EMPA-REG OUTCOME, LEADER, SUSTAIN-6, CANVAS, DECLARE-TIMI 58 Trials
5. DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved Trials (Heart Failure)
6. CREDENCE, DAPA-CKD Trials (Kidney Disease)
7. FDA Drug Safety Communications - Diabetes Medications
